Benjamin Bader
Director / Head of Screening, Nuvisan
Benjamin Bader is listed as Director / Head of Screening, Nuvisan. Benjamin is scheduled to speak at SLAS 2027 International Conference & Exhibition on 30 January 2027.
Compiled from published conference agendas; not yet confirmed by Benjamin. Is this you? Claim this profile.
About
Benjamin Bader graduated in Human Biology at the University of Marburg, Germany, followed by a PhD at the Max-Planck-Institute for Molecular Physiology in Dortmund, Germany. After a post-doctoral work in Biotech at Vasopharm GmbH, his industrial career in pharmaceutical research started in 2001 at Schering AG, Berlin. Soon after the transition to Bayer AG in 2006 he became group leader of Cell-based Assay Development & HTS. In 2020 he was appointed Director / Head of High-Throughput Screening guiding the HTS team into the newly formed NUVISAN ICB GmbH providing drug discovery, assay development and screening services as a CRO for clients all over the world. Benjamins personal research interests have been mainly in oncology in the fields of signal transduction (Ras-pathway), cell cycle (spindle checkpoint), immune-oncology, DNA-damage signalling and hormone-dependent tumours.
Upcoming
SLAS 2027 International Conference & Exhibition 30 January 2027 – 3 February 2027
- Assay Guidance Workshop for High-Throughput Screening and Lead Discovery Speaker · 30 January 2027
Spoke alongside
People who have shared a session with Benjamin at events on B2DB.
- Jayme Dahlin Medical Director, Clinical Development · Oruka Therapeutics 1 shared session
- Joe Trask Life Sciences Segment Manager, NA · Revvity 1 shared session
- Michelle Arkin Professor, Pharm Chem; co-Director, Small Molecule Discovery Center · University of California - San Francisco 1 shared session
- Nathan Coussens Scientific Director, Molecular Pharmacology Laboratory · Frederick National Laboratory for Cancer Research 1 shared session
- Sarine Markossian Editor-in-Chief, Assay Guidance Manual (AGM) and Lead, AGM Translational Science Resources Program · NCATS/NIH 1 shared session
- Stefan Grotegut Executive Director, High-Throughput Screening · Eli Lilly and Company 1 shared session
- Terry Riss Scientific Ambassador · Promega Corporation 1 shared session
- Thomas D.Y. Chung Director, Translational Programs Outreach · Sanford Burnham Prebys Medical Discovery Institute 1 shared session